Table 1.
Analyzed cohorts.
Fig 1.
TERT expression and immune signatures.
(A) Five out of six cohorts showed correlation of TERT expression and a CD4+ Th1 T cell immune signature (xCell assay). (B) Expression of T cell exhaustion markers in single CD4+ T cells of patients with low vs. high TERT expression in malignant tumor cells (</>0.05 TPM). Jerby-Arnon cohort, pre-therapy samples. Th1: T-helper type 1; TME: tumor microenvironment; TPM: transcripts per million; xCell: xCell cell types enrichment analysis. The figure was created with BioRender.com.
Fig 2.
Primary tumor thickness and TERT in corresponding metastases.
(A) Breslow depth of primaries with TERT promoter mutations and TERT expression measured in corresponding metastatic tumors of the SKCM cohort (without one outlier; TERT expression >600, for data including outliers see S8 Fig in S1 File; also see S3D Table). (B) TERT expression in metastatic tumors arising from thin (Breslow depth <2 mm) and thick tumors (>2 mm). Information on TERT alterations in thin primaries are not available. TERTpm: TERT promoter mutations; TPM: transcripts per million. The figure was created with BioRender.com.
Fig 3.
Genetic associates of TERT alterations.
(A) TERT alterations and exome mutation load in the SKCM cohort. (B) TERT expression and DNA repair genes associated across all cohorts. (C) TERT alterations, mitochondrial mutation load and hypoxia (PCAWG cohort). TPM: transcripts per million; FPKM: fragments per kilobase of transcript per million fragments mapped; nsSNP: non-synonymous mitochondrial SNP; TERTpm: TERT promoter mutations. The figure was created with BioRender.com.
Table 2.
Genes repeatedly associated with TERT mRNA in 9 cohorts (S7 Table).